All In Biotech

Drug Trial Radar · NCT07920172

Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)

Randomized, Multi-cohort, Controlled Phase I/II Clinical Trials Evaluating the Safety, Tolerability and Immunogenicity of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cell) for Vaccination in Healthy Subjects Aged 40 Years and Above

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

May 23, 2029

Study completion May 23, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A seamless Phase I/II trial evaluating the immunogenicity and safety of a recombinant herpes zoster ZFA01 adjuvanted vaccine (CHO cell) in healthy adults aged ≥40 years. Phase I (n=100): randomized, blinded, placebo-controlled, age/dose escalation across 4 cohorts. Phase II (n=400): randomized, open-label, active-controlled, with 1:1 or 1:1:1 allocation to two experimental groups and a positive control group across three age strata.

Conditions

  • Herpes Zoster

Interventions

  • Low-dose adjuvanted recombinant zoster vaccineBiological

    0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 375 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 30.

  • High-dose adjuvanted recombinant zoster vaccine (0 and 30 days schedule)Biological

    0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 750 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 30.

  • High-dose adjuvanted recombinant zoster vaccine (0 and 60 days schedule)Biological

    0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 750 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 60.

  • Low-dose adjuvant placeboBiological

    0.5 mL per dose, containing 375 μg adjuvant only, no varicella-zoster virus glycoprotein E (gE), intramuscular administration, 2 doses at Day 0 and Day 30.

  • High-dose adjuvant placeboBiological

    0.5 mL per dose, containing 750 μg adjuvant only, no varicella-zoster virus glycoprotein E (gE), intramuscular administration, 2 doses at Day 0 and Day 30.

  • Zoster Vaccine Recombinant, AdjuvantedBiological

    0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE), adjuvanted with AS01B, intramuscular administration, 2 doses at Day 0 and Day 60.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoints(1):Occurrence of all AEsTime frame: within 30 days after each dose of vaccination
  2. Safety Endpoints(2):Occurrence of all SAEsTime frame: from the first dose up to 12 months after completion of the full vaccination series
  3. Safety Endpoints(3):Occurrence of all pIMDsTime frame: from the first dose up to 12 months after completion of the full vaccination series
  4. Immunogenicity Endpoints (1): GMTs of VZV gE antibody and VZV antibodyTime frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
  5. Immunogenicity Endpoints (2): GMIs of VZV gE antibody and VZV antibodyTime frame: at 30 days, 6 months, and 12 months after completion of full vaccination series
  6. Immunogenicity Endpoints (3): Seropositivity rates of VZV gE antibody and VZV antibodyTime frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
  7. Immunogenicity Endpoints (4): Seroconversion rates of VZV gE antibody and VZV antibody.Time frame: at 30 days after completion of full vaccination series
  8. Immunogenicity Endpoints (5): Detection frequency of CD4²⁺ T cells secreting at least two gE-specific cytokines (IFN-γ, IL-2, TNF-α, CD40L, IL-17A)Time frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
  9. Percentage of Participants With Clinically Significant Serum Chemistry Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
  10. Percentage of Participants With Clinically Significant Hematology Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
  11. Percentage of Participants With Clinically Significant Urinalysis Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
  12. Percentage of Participants With Clinically Significant Coagulation Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guangxi Zhuang Autonomous Region People's Hospital

    Guangxi, Nanning, China · Recruiting

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    Guangxi, Nanning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.